The factory in Langreo will go from producing 4,800 tonnes per year to 6,000 tonnes per year

The German multinational Bayer is to invest €6 million to expand the capacity of its facilities at Lada, in Langreo (Asturias). The aim of this investment is to increase the production of acetylsalicylic acid, the active ingredient used in the preparation of Aspirin, by 25%.


Thanks to this expansion plan, to be completed within one year, the factory in Langreo will go from producing 4,800 tonnes per year to 6,000 tonnes per year.


What does this new investment in Asturias mean for Bayer?

The nearly €6 million investment in the Bayer acetylsalicylic acid plant in Langreo, Asturias, will enable these facilities to expand their production capacity by 20 to 25%, which means that later this year this Spanish factory will take over 100% of world production of the active ingredient used in Aspirin. Specifically, these facilities will now produce about 6,000 tonnes of acetylsalicylic acid.


Will new equipment be acquired for the manufacturing process of acetylsalicylic acid?

Yes, Bayer will be installing new equipment for the different stages of manufacturing, particularly in the processes of crystallisation, centrifugation and drying and will be augmenting capacity at the ancillary energy and distillation facilities. The expansion work will be done throughout 2013 with a view to beginning operation in early 2014.


Will any new jobs be created through this investment?

The increase in capacity at the Langreo factory has involved the hiring of about 20 employees for the time spent on the expansion of the facilities. When will Bayer’s expansion plan at Lada be complete? The process of raising the productive capacity of the Bayer plant at Langreo is scheduled to end in 2013 and full operation is expected by 2014.


Has worldwide demand for Aspirin increased in recent years?

The consumption of the active ingredient in Aspirin has increased in recent years, which is particularly due to the increase in demand for products such as the antithrombotic drug Adiro® and its new presentations for the American and European markets. Specifically, Bayer estimates that consumption of acetylsalicylic acid will grow between 5 and 8% annually over the next few years.